870521-33-8

Usage

Uses

Used in Organic Synthesis:
2-Morpholinopyrimidin-5-ylboronic acid is used as a key intermediate in organic synthesis for the creation of various biologically active molecules, leveraging its ability to form stable complexes with diols.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-Morpholinopyrimidin-5-ylboronic acid is employed as a building block for the synthesis of pharmaceutical compounds, contributing to the development of new drugs with potential therapeutic applications.
Used in Drug Discovery:
2-Morpholinopyrimidin-5-ylboronic acid is utilized in drug discovery efforts, where its unique chemical properties aid in the identification and optimization of new drug candidates with potential efficacy in treating various diseases.
Used in the Treatment of Neurological Disorders:
2-Morpholinopyrimidin-5-ylboronic acid is studied for its potential use in the treatment of neurological disorders, given its interaction with biological targets that may be implicated in such conditions.
Used in Cancer Therapy:
2-Morpholinopyrimidin-5-ylboronic acid is also being investigated for its potential role in cancer therapy, where it may contribute to the development of novel treatment strategies for various types of cancer.
Used in Chemical Reaction Development:
2-Morpholinopyrimidin-5-ylboronic acid is applied in the development of new chemical reactions, taking advantage of its reactivity and complex-forming ability with diols to advance synthetic methodologies in chemistry.

InChI:InChI=1/C8H12BN3O3/c13-9(14)7-5-10-8(11-6-7)12-1-3-15-4-2-12/h5-6,13-14H,1-4H2

Upstream product

• 84539-22-0 4-(5-bromopyrimidin-2-yl)morpholine 
• 110-91-8 morpholine 
• 1003845-06-4 (2-chloropyrimidin-5-yl)boronic acid 

Downstream Products

• 1435972-29-4 C₂₇H₃₃N₇O₄ 
• 1206797-76-3 C₂₄H₂₃N₃O₄S₂ 
• 1206797-72-9 C₂₄H₂₃N₃O₄S₂ 

Relevant academic research and scientific papers

FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of substituted benzimidazole, imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of substituted benzimidazole, imidazo[1,2-α]pyridine and pyrazolo[1,5- α]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human a

FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of substituted fused tricyclic imidazole derivatives, in particular dihydro- 1H-pyrano[4',3':4,5]imidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4- c']dipyridine, dihydro-1H-pyrano[3',4':4,5]imidazo[1,2-a]pyridine and tetrahydro-6H- cyc

FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of fused tricyclic imidazole derivatives, in particular dihydro-1H-cyclopenta[4,5]imidazo[1,2-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of tricyclic benzimidazole derivatives, in particular dihydro-1H- imidazo [1,2-a]benzimidazo le, dihydro-1H-pyrrolo [1,2-a]benzimidazo le, dihydro-1H- pyrazino[1,2-a]benzimidazole, dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole and dihydrothiazolo[3,4-a]benzimidazolem, and analogues thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

PYRAZOLOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of substituted pyrazolo[1,5-a]pyridine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

TRIAZOLOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of substituted [1,2,4]triazolo[4,3-b]pyridazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflamma

IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of substituted imidazo[1,2-b]pyridazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory dis

TRIAZOLOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of substituted [l,2,4]triazolo[4,3-α]pyridine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; n

IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of imidazo[l,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.